Novocure (NVCR) Misses Q1 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Novocure Reports First Quarter 2016 Financial Results and Provides Company Update
May 9, 2016 4:00 PM EDTIncreasing adoption of Optune with 755 prescriptions received in the first quarter 2016, an increase of 73 percent from the first quarter 2015 and 36 percent from the fourth quarter 2015
797 active patients at March 31, 2016, an increase of 114 percent from March 31, 2015 and 32 percent from December 31, 2015
First quarter 2016 reported revenues of $13.1 million, reflecting 151 percent growth versus first quarter 2015
More than 112 million Americans have coverage of Optune as a treatment for newly diagnosed and/or recurrent glioblastoma
Phase 2 pilot PANOVA results presented at ASCO GI suggest Tumor Treating Fields plus chemotherapy may be safe as first-line treatment and improve survival of patients... More
